GMABGenmab A/S
What is the market doing?
No clear lean: nothing decisive, though in an uptrend.
In an uptrend, above its rising 50- and 200-day averages. Price is +45% vs its 200-day average.
A token position, settled Sep 30, 2026, a few days of normal trading to cover. Up 23% since the previous count, down from 1.3% of shares outstanding three months ago.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How GMAB is trading
Genmab A/S is +34% over the past year while the S&P 500 is +16%: 18 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- +45%
vs 200-day average · a clear uptrend
- RSI (14)
- 70
RSI (14) · neutral
- Below its 52-week high
- 0.00%
Below its 52-week high
Details›
- Last close2026-10-23
- $43.78
- 1 monthS&P 500 −0.94%
- +26%
- 1 yearS&P 500 +16%
- +34%
- 5 yearsS&P 500 +86%
- +4.2%
- vs 50-day average$35.16
- +25%
- 52-week high
- $43.77
- 52-week low
- $23.85
- Annualised volatility
- 36%
| Year | Return |
|---|---|
| 2026 (year to date) | +42% |
| 2025 | +48% |
| 2024 | −34% |
| 2023 | −25% |
| 2022 | +7.1% |
| 2021 | −2.7% |
| 2020 | +82% |
| 2019 | +36% |
| 2018 | −0.61% |
| 2017 | −0.04% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | −1.6% |
| Feb | 10 | 5 of 10 | +1.7% |
| Mar | 10 | 5 of 10 | −1.4% |
| Apr | 10 | 5 of 10 | +2.4% |
| May | 10 | 5 of 10 | +0.35% |
| Jun | 10 | 7 of 10 | +1.6% |
| Jul | 11 | 9 of 11 | +6.4% |
| Aug | 11 | 7 of 11 | +3.4% |
| Sep | 11 | 3 of 11 | −1.6% |
| Oct | 11 | 4 of 11 | −1.3% |
| Nov | 10 | 7 of 10 | +6.4% |
| Dec | 10 | 4 of 10 | −2.6% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.